207 related articles for article (PubMed ID: 31215336)
21. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
22. Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension.
Raina A; Coons JC; Kanwar M; Murali S; Sokos G; Benza RL
Pulm Circ; 2013 Jan; 3(1):116-20. PubMed ID: 23662183
[TBL] [Abstract][Full Text] [Related]
23. Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center.
Chin KM; Ruggiero R; Bartolome S; Velez-Martinez M; Darsaklis K; Kingman M; Harden S; Torres F
Pulm Circ; 2015 Sep; 5(3):513-20. PubMed ID: 26401252
[TBL] [Abstract][Full Text] [Related]
24. Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations.
Ramani G; Cassady S; Shen E; Broderick M; Wasik A; Sui Q; Nelsen A
Pulm Circ; 2020; 10(3):2045894020923956. PubMed ID: 35154662
[TBL] [Abstract][Full Text] [Related]
25. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
26. A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil.
Zwicke DL; Restrepo-Jaramillo R; Alnuaimat H; Gordon K; Broderick M; Edwards LD; Allmon A; Leary PJ
Pulm Circ; 2021; 11(1):2045894021998203. PubMed ID: 33738096
[TBL] [Abstract][Full Text] [Related]
27. Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil.
Kingrey JF; Miller CE; Franco V; Smith JS; Zolty R; Oudiz RJ; Elwing JM; Huston JH; Melendres-Groves L; Ravichandran A; Balasubramanian V; Wu B; Hwang S; Seaman S; Broderick M; Rahaghi FF
Pulm Circ; 2023 Jul; 13(3):e12255. PubMed ID: 37497167
[TBL] [Abstract][Full Text] [Related]
28. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
29. Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature.
Smith ZR; Kelly B; Awdish RL; Hegab S
J Pharm Pract; 2019 Oct; 32(5):599-604. PubMed ID: 29558853
[TBL] [Abstract][Full Text] [Related]
30. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
32. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
[TBL] [Abstract][Full Text] [Related]
33. The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension.
Lindegaard Pedersen M; Krüger M; Grimm D; Infanger M; Wehland M
Basic Clin Pharmacol Toxicol; 2020 Jan; 126(1):32-42. PubMed ID: 31403254
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.
Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM
Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763
[TBL] [Abstract][Full Text] [Related]
35. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.
Miller CE; Franco V; Smith JS; Balasubramanian V; Kingrey J; Zolty R; Melendres-Groves L; Huston J; Elwing JM; Ravichandran A; Cella D; Shen E; Seaman S; Thrasher CM; Broderick M; Oudiz RJ
Respir Med; 2023 Nov; 218():107374. PubMed ID: 37532157
[TBL] [Abstract][Full Text] [Related]
36. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
37. Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
Maestas T; Hansen LM; Vanderpool RR; Desai AA; Airhart S; Knapp SM; Cohen A; Feldman J; Rischard FP
Pulm Circ; 2018; 8(4):2045894018797270. PubMed ID: 30124133
[TBL] [Abstract][Full Text] [Related]
38. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.
Tapson VF; McLaughlin VV; Gomberg-Maitland M; Widlitz AC; Krichman AD; Laliberte KJ; Zaccardelli DS; Barst RJ
J Vasc Access; 2006; 7(3):112-7. PubMed ID: 17019662
[TBL] [Abstract][Full Text] [Related]
39. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
Ivy DD; Claussen L; Doran A
Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
[TBL] [Abstract][Full Text] [Related]
40. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
